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CASE REPORT
Coexistence of double primary cancers in the same
patient is rare. Myoga et al reported the first case
of synchronous primary ovarian cancer and renal
cell carcinoma (RCC) in 1988.1 To date, only spo-
radic cases have been reported. Despite the fact
that the association between RCC and steroid-
hormone target organs (breasts, uterus, ovaries)
has been described, the pathogenesis of such dis-
ease is unclear. The clinical differentiation between
double primary and metastatic tumors remains
difficult. Therefore, we report a case diagnosed with
coexistence of double primary cancers involving
the right ovary and right kidney.
Case Report 
A 58-year-old G6P4 woman presented with an
enlarged girdle length for about 3 months. She
had menarche at the age of 13 and went through
menopause at the age of 55. She had never 
undergone hormone replacement therapy. Abdo-
minal sonography and computed tomography
(CT) showed a right cystic adnexal mass measur-
ing 10 × 10 cm, and another well-defined tumor
about 3 × 2 cm at the right kidney (Figures 1 and
2). The CA-125 serum level was 80.8 U/mL (nor-
mal, < 35 U/mL). The patient then underwent
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debulking surgery (total abdominal hysterectomy
with bilateral salpingo-oophorectomy, pelvic
lymph node dissection, and omentectomy) for
the ovarian cancer and radical nephrectomy for
the right renal tumor. Pathology revealed right
ovarian clear-cell carcinoma with peritoneal,
omental, and bilateral fallopian tube metastasis
(Figure 3), along with conventional clear-cell-
type RCC without evidence of extrarenal involve-
ment (Figure 4). Immunohistochemical staining
for RCC showed strongly positive results in epi-
thelial membrane antigen (EMA) staining and
negative results in estrogen receptor (ER), prog-
esterone receptor (PR), 34βE12, and vimentin
staining. Ovarian clear-cell carcinoma showed
weakly positive results in EMA staining and neg-
ative results in ER, PR, 34βE12, and vimentin
staining. The pathologic staging was pT1N0M0
for RCC, and stage IIIC (pT3cN0M0) for ovarian
cancer.
The patient’s postoperative CA-125 level was
5.2 U/mL. After completing six courses of adjuvant
chemotherapy with paclitaxel and carboplatin,
tumor recurrence with multiple liver and lung
metastases was found by CT scan. The chemother-
apy regimen was then shifted to liposomal, doxoru-
bicin, and carboplatin for three courses. However,
a poor response was noted. The patient died of
disseminated metastasis due to ovarian cancer
about 20 months after operation.
Discussion
Multiple malignancies in the same patient have
been reported to present in 1.84–3.9% of all 
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Figure 1. A 2.4-cm well-defined tumor mass at the right
kidney with mild enhancement.
Figure 2. Huge adnexal cystic tumor (15 × 14 × 17.5 cm) is
noted with heterogeneous peripheral enhancement.
Figure 3. Clear-cell carcinoma of the ovary with tubular and
tubulopapillary growth pattern (hematoxylin & eosin, 100×).
Figure 4. Conventional clear-cell-type renal cell carcinoma
(hematoxylin & eosin, 100×).
cancers.2 Coexistence of double primary tumors
in one individual is extremely rare. Einer et al re-
ported 30 years of data that included 3863 cases
of female gynecologic malignancies. Among them,
26 (0.7%) patients with synchronous primary
cancers were identified. The most frequent coex-
istent tumors were ovarian and endometrial can-
cers. Cases of primary ovarian and RCC were not
identified in that study.3,4 Myoga et al published
the first case of synchronous primary ovarian and
renal cancers in 1988.1 To date, only sporadic cases
have been reported. 
The pathogenesis for synchronous malignancies
in the same patient is not entirely clear. However,
common etiologies, such as exposure to the same
hormone or carcinogen, are often suspected.5 Some
RCCs have been thought to be hormone depend-
ent. The association between RCC and steroid-
hormone target organs (breasts, uterus, ovaries)
may be explained by such a hypothesis. Di Silverio
et al reported 17 cases of RCCs associated with sec-
ond primary neoplasms occurring in steroid-
hormone target tissues. Among them, 10 RCCs
were associated with breast carcinoma, four with
endometrial carcinoma, and only three with
ovarian carcinoma.6 We reviewed the data in our
hospital, and only one patient was noted to have
coexistence of ovarian cancer and RCC out of a
total of 584 patients with RCC from 1982 to 2002.
In recent years, several authors have studied
steroid-receptor molecules in kidneys. Bath et al
demonstrated the presence of estradiol receptors
in hamster kidneys.7 Bullock and Bardin revealed
the existence of androgen receptors in mouse
kidneys.8 The cytosol from normal human kidney
specimens showed binding activity for steroid hor-
mones, which was related to a receptor specific
only for estradiol and progesterone.9
Several reports have described the presence of
androgen receptors, ER, and PR, in RCC tissue.10,11
In addition, chronic administration of estradiol
or diethylstilbestrol to male Syrian hamsters in-
duced kidney tumors, and simultaneous admin-
istration of the antiestrogen nafoxidine completely
inhibited tumor formation.12 Banerjee et al also
found that estradiol induced the development of
micronuclei and aneuploidy in renal tissue.13
How estrogen induces tumorigenesis in the kid-
ney remains to be clarified. However, we did not
detect the presence of ER and PR in the RCC of
our case.
The relationship among reproductive factors,
steroid hormones, and RCC has been studied in
international investigations carried out between
1989 and 1991 on 608 women with RCC and 766
female controls.14,15 A significant trend in the risk
of developing RCC is associated with the number
of births, with an excessive 80% risk being found
in six or more births as compared with one birth.
A decreased risk was found for increasing age at
menarche and for increasing age at the first birth;
in contrast, the age at menopause or estrogen-
replacement therapy was unrelated to the risk of
developing RCC. Our patient had menarche at the
age of 13 and went through menopause at the
age of 55. Her reproductive history was G6P4, and
she had no history of exogenous hormone replace-
ment therapy. Her age during the first delivery
was 21. In this regard, she would have been ex-
pected to be at risk for developing RCC in terms of
menstrual and reproductive history.
Metastasis is often determined if synchronous
tumors have similar histologies. To make a defini-
tive diagnosis of coexistent double tumors, distinc-
tively different histologies should be observed. 
In 1932, Warren and Gates described criteria for
making a diagnosis of coexistent primary tumors.
These criteria included the following: (1) each of
the tumors must present a definite picture of ma-
lignancy; (2) each tumor must be distinct; (3) the
probability of one tumor being a result of metasta-
sis of the other must be excluded.2 However, the
differentiation between metastatic tumors and
double primary tumors sometimes poses a diag-
nostic challenge. In our case, the patient’s ovarian
cancer was clear-cell carcinoma with a tubular
and tubulopapillary growth pattern. The kidney
showed a conventional clear-cell renal carcinoma.
The pathology distinguished between the two pri-
mary tumors clearly, excluding the possibility of
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metastasis. In general, the presence of a solid or
tubular growth pattern comprising clear cells
within a prominent vascular network was the his-
tologic characteristic of clear-cell-type RCC. How-
ever, ovarian clear-cell carcinoma showed clear
cells with frequent hobnail appearance, which
were arranged in tubules and occasional cystic
change. The clear cells may line complex papillae
variably containing periodic acid-Schiff-positive
hyaline basement membrane material expanding
the papillary cores. If the differentiation in histol-
ogy is not clear, immunohistochemical staining
with a panel of antibodies, including cytokeratins
(CK5, CK6, CK7), ER, PR, vimentin, EMA, CA-
125, 34βE12, CD10, and RCC antibody could be
helpful. In general, RCCs, particularly the clear-
cell types, demonstrate a weakly positive or neg-
ative staining for cytokeratins (CK5, CK6, CK7),
34βE12, CA-125, PR, and ER but demonstrate
positive staining for vimentin and RCC antibody.
Some RCCs can show a coexpression of both cyto-
keratins and vimentin. Ovarian clear-cell carci-
noma is usually positive for PR, ER, and CA-125
but negative for 34βE12 and vimentin.16 In our
case, RCC staining showed strongly positive re-
sults in EMA staining and negative results in CK,
ER, PR, 34βE12, and vimentin staining. Ovarian
cancer showed weakly positive results in EMA
staining and negative results in CK, ER, PR,
34βE12, and vimentin staining. CD10 was used
to reliably distinguish RCC of clear-cell and pap-
illary types. Some reported the utility of CD10 in
the diagnosis of metastatic RCC by fine-needle
aspiration biopsy but the diagnostic usefulness is
limited because of its low specificity.17
Preoperative diagnosis to differentiate between
coexistent double cancers and metastasis may 
be difficult. In preoperative imaging studies (CT
or MRI), renal metastases are usually small, mul-
tiple, bilateral, wedge-shaped, less exophytic,
and are located within the renal capsule. In con-
trast, primary RCC is usually single, unilateral,
nonwedge-shaped, and exophytic, as seen in our
case.18
Although extremely rare, the possibility of 
coexistent RCC and ovarian cancer should be
considered in clinical practice. Careful attention
should be paid to the differential diagnosis be-
tween double primary and metastatic tumors,
based on the pathologic and clinical characteristics.
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